GSK (LON:GSK) Price Target Lowered to GBX 1,400 at JPMorgan Chase & Co.

Key Points

• JPMorgan Chase & Co. has lowered its price target for GSK from GBX 1,460 to GBX 1,400, maintaining an "underweight" rating on the stock.
• Other analysts have mixed opinions, with Deutsche Bank setting a GBX 1,450 target and Shore Capital a more optimistic GBX 2,000 target for GSK.
• On the trading day, GSK shares opened at GBX 1,390, reflecting a 0.5% decline in value.

GSK (LON:GSK - Free Report) had its price target trimmed by JPMorgan Chase & Co. from GBX 1,460 ($19.63) to GBX 1,400 ($18.83) in a report issued on Monday morning, Marketbeat reports. They currently have an underweight rating on the stock.

A number of other research analysts have also commented on GSK. Shore Capital reiterated a "buy" rating and set a GBX 2,000 ($26.90) price target on shares of GSK in a report on Wednesday, July 30th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a GBX 1,450 ($19.50) target price on shares of GSK in a research note on Thursday, July 31st. Finally, Berenberg Bank restated a "hold" rating and issued a GBX 1,600 ($21.52) target price on shares of GSK in a research note on Friday, July 18th.

GSK Stock Performance

Shares of GSK stock traded up GBX 12.50 ($0.17) during trading hours on Monday, reaching GBX 1,395.50 ($18.77). 5,052,597 shares of the company's stock were exchanged, compared to its average volume of 13,202,021. GSK has a fifty-two week low of GBX 1,242.50 ($16.71) and a fifty-two week high of GBX 1,678.68 ($22.58). The stock has a market capitalization of £56.63 billion, a P/E ratio of 22.54, a P/E/G ratio of 1.24 and a beta of 0.31. The business has a fifty day moving average price of GBX 1,430.07 and a 200-day moving average price of GBX 1,426.52. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64.

GSK (LON:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported GBX 75.30 ($1.01) EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Analysts predict that GSK will post 175.980975 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Wendy Becker bought 545 shares of the business's stock in a transaction that occurred on Friday, June 20th. The stock was acquired at an average cost of GBX 1,435 ($19.30) per share, for a total transaction of £7,820.75 ($10,517.42). Also, insider Jonathan Symonds purchased 1,350 shares of the stock in a transaction on Friday, June 20th. The stock was bought at an average price of GBX 1,435 ($19.30) per share, for a total transaction of £19,372.50 ($26,052.31). Insiders purchased 1,905 shares of company stock valued at $2,732,835 over the last 90 days. 1.61% of the stock is currently owned by corporate insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.